Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment.

Treatment of human breast or colon carcinoma cells with recombinantly derived human leukocyte (clone A) interferon (IFN-alpha A) increases the surface expression of specific tumor-associated antigens (TAAs) recognized by monoclonal antibodies (MAbs). The MAbs used, B1.1, B6.2, and B72.3, recognize three distinct TAAs, i.e., the Mr 180,000 carcinoembryonic antigen, a Mr 90,000, and a Mr 220,000 to 400,000 glycoprotein, respectively. The binding of the MAbs to the surface of tumor cells increased in a dose-dependent manner, with optimal levels of TAA enhancement at 100 to 1,000 units IFN-alpha A/ml. Higher concentrations of IFN-alpha A that were cytostatic or cytotoxic were also less effective in enhancing TAA expression. Human melanoma (A375) cells and normal fibroblasts (WI-38 and Flow 4000) do not express any of the three TAAs, either before or after interferon treatment. The ability of IFN-alpha A to increase the expression of TAAs on human carcinoma cells was also temporally dependent, with optimal enhancement occurring after 16 to 24 hr. The enhancement of specific TAAs at the surface of the carcinoma cells by IFN-alpha A was confirmed, using fluorescence-activated cell sorter analysis. These data demonstrate that the IFN-alpha A-mediated increase of surface antigen is a result of both an accumulation of more antigen per cell, and an increase in the percentage of cells expressing the antigen. The ability of recombinant interferon to enhance specific TAAs on human carcinoma cells may be exploited in designing protocols for the in situ detection and therapy of human carcinoma lesions by MAbs, as well as in further defining the role of specific TAAs in the expression of the transformed phenotype.

[1]  I. Gresser.  The antitumor effects of interferon , 1986, Biochimica et biophysica acta.

[2]  S. Lee,et al.  Importance of treatment regimen of interferon as an antitumor agent. , 1983, Cancer research.

[3]  S. Pestka.  The human interferons--from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond. , 1983, Archives of biochemistry and biophysics.

[4]  J. Schlom,et al.  Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. , 1983, Cancer research.

[5]  P. Hand,et al.  Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. , 1983, Cancer research.

[6]  S. Pestka,et al.  Differential effect of recombinant human leukocyte interferon on human leukemic and normal myeloid progenitor cells. , 1982, Biochemical and biophysical research communications.

[7]  F. Balkwill,et al.  Human interferon inhibits the growth of established human breast tumours in the nude mouse , 1982, International journal of cancer.

[8]  T. Merigan,et al.  Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Merigan,et al.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. , 1982, Annals of internal medicine.

[10]  M. Fellous,et al.  Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Lee,et al.  Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon subtypes. , 1982, Cancer research.

[12]  J. Taylor‐Papadimitriou,et al.  Effects of human lymphoblastoid interferon on cultured breast cancer cells , 1981, International journal of cancer.

[13]  S. Pestka,et al.  Human leukocyte interferon produced by E. coli is biologically active , 1980, Nature.

[14]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[15]  M. Capobianchi,et al.  Human interferon-gamma enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-alpha and interferon-beta. , 1983, Infection and immunity.

[16]  H. Holtmann,et al.  A comparison of the antiproliferative and antiviral activities of alpha-, beta- and gamma-interferons: description of a unified assay for comparing both effects simultaneously. , 1981, Journal of immunological methods.